Hematopoietic stem cell transplantation in Oman

D. Dennison, S. Al Kindi, A. Pathare, S. Daar, N. Nusrat, J. Ur Rehman, F. Zia, H. Khan, M. Khan, A. Alghazaly, S. Al Zadjali, M. Tauro, A. T. Al Lawatia, S. S. Ganguly

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Hematopoietic SCT (HSCT) is an integral part of the management of patients with hematologic disorders. The Sultanate of Oman, with a population of 2.3 million, has an HSCT program based in the Sultan Qaboos University (SQU) hospital. Initiated in 1995, this two-bed unit continues to be the only program in the country. Between June 1995 and August 2006, a total of 128 patients underwent HSCT in this center, averaging about 10-12 transplants per year. The median age of these patients was 11 years (2 months to 45 years). Hematologic malignancies (49%) and inherited disorders (42%) constituted the major transplant indications, whereas BM failure accounted for the remaining. The majority of transplants carried out so far have been HLA-matched sibling-donor allogeneic HSCTs. Among the inherited disorders, homozygous beta-thalassemia and primary immunodeficiency are important transplant indications in this center. The approximate cost of an uncomplicated transplant in this center is US$50000. The success of this program has now led to the initiation of a new and larger HSCT complex to provide the opportunity for more patients to benefit from this treatment modality within the country.

Original languageEnglish
JournalBone Marrow Transplantation
Volume42
Issue numberSUPPL.1
DOIs
Publication statusPublished - 2008

Fingerprint

Oman
Hematopoietic Stem Cell Transplantation
Transplants
beta-Thalassemia
Hematologic Neoplasms
Siblings
Tissue Donors
Costs and Cost Analysis
Population

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

Hematopoietic stem cell transplantation in Oman. / Dennison, D.; Al Kindi, S.; Pathare, A.; Daar, S.; Nusrat, N.; Ur Rehman, J.; Zia, F.; Khan, H.; Khan, M.; Alghazaly, A.; Al Zadjali, S.; Tauro, M.; Al Lawatia, A. T.; Ganguly, S. S.

In: Bone Marrow Transplantation, Vol. 42, No. SUPPL.1, 2008.

Research output: Contribution to journalArticle

Dennison, D, Al Kindi, S, Pathare, A, Daar, S, Nusrat, N, Ur Rehman, J, Zia, F, Khan, H, Khan, M, Alghazaly, A, Al Zadjali, S, Tauro, M, Al Lawatia, AT & Ganguly, SS 2008, 'Hematopoietic stem cell transplantation in Oman', Bone Marrow Transplantation, vol. 42, no. SUPPL.1. https://doi.org/10.1038/bmt.2008.131
Dennison, D. ; Al Kindi, S. ; Pathare, A. ; Daar, S. ; Nusrat, N. ; Ur Rehman, J. ; Zia, F. ; Khan, H. ; Khan, M. ; Alghazaly, A. ; Al Zadjali, S. ; Tauro, M. ; Al Lawatia, A. T. ; Ganguly, S. S. / Hematopoietic stem cell transplantation in Oman. In: Bone Marrow Transplantation. 2008 ; Vol. 42, No. SUPPL.1.
@article{87b7d96cad6a44c0bf662f59f8f1c46c,
title = "Hematopoietic stem cell transplantation in Oman",
abstract = "Hematopoietic SCT (HSCT) is an integral part of the management of patients with hematologic disorders. The Sultanate of Oman, with a population of 2.3 million, has an HSCT program based in the Sultan Qaboos University (SQU) hospital. Initiated in 1995, this two-bed unit continues to be the only program in the country. Between June 1995 and August 2006, a total of 128 patients underwent HSCT in this center, averaging about 10-12 transplants per year. The median age of these patients was 11 years (2 months to 45 years). Hematologic malignancies (49{\%}) and inherited disorders (42{\%}) constituted the major transplant indications, whereas BM failure accounted for the remaining. The majority of transplants carried out so far have been HLA-matched sibling-donor allogeneic HSCTs. Among the inherited disorders, homozygous beta-thalassemia and primary immunodeficiency are important transplant indications in this center. The approximate cost of an uncomplicated transplant in this center is US$50000. The success of this program has now led to the initiation of a new and larger HSCT complex to provide the opportunity for more patients to benefit from this treatment modality within the country.",
author = "D. Dennison and {Al Kindi}, S. and A. Pathare and S. Daar and N. Nusrat and {Ur Rehman}, J. and F. Zia and H. Khan and M. Khan and A. Alghazaly and {Al Zadjali}, S. and M. Tauro and {Al Lawatia}, {A. T.} and Ganguly, {S. S.}",
year = "2008",
doi = "10.1038/bmt.2008.131",
language = "English",
volume = "42",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",
number = "SUPPL.1",

}

TY - JOUR

T1 - Hematopoietic stem cell transplantation in Oman

AU - Dennison, D.

AU - Al Kindi, S.

AU - Pathare, A.

AU - Daar, S.

AU - Nusrat, N.

AU - Ur Rehman, J.

AU - Zia, F.

AU - Khan, H.

AU - Khan, M.

AU - Alghazaly, A.

AU - Al Zadjali, S.

AU - Tauro, M.

AU - Al Lawatia, A. T.

AU - Ganguly, S. S.

PY - 2008

Y1 - 2008

N2 - Hematopoietic SCT (HSCT) is an integral part of the management of patients with hematologic disorders. The Sultanate of Oman, with a population of 2.3 million, has an HSCT program based in the Sultan Qaboos University (SQU) hospital. Initiated in 1995, this two-bed unit continues to be the only program in the country. Between June 1995 and August 2006, a total of 128 patients underwent HSCT in this center, averaging about 10-12 transplants per year. The median age of these patients was 11 years (2 months to 45 years). Hematologic malignancies (49%) and inherited disorders (42%) constituted the major transplant indications, whereas BM failure accounted for the remaining. The majority of transplants carried out so far have been HLA-matched sibling-donor allogeneic HSCTs. Among the inherited disorders, homozygous beta-thalassemia and primary immunodeficiency are important transplant indications in this center. The approximate cost of an uncomplicated transplant in this center is US$50000. The success of this program has now led to the initiation of a new and larger HSCT complex to provide the opportunity for more patients to benefit from this treatment modality within the country.

AB - Hematopoietic SCT (HSCT) is an integral part of the management of patients with hematologic disorders. The Sultanate of Oman, with a population of 2.3 million, has an HSCT program based in the Sultan Qaboos University (SQU) hospital. Initiated in 1995, this two-bed unit continues to be the only program in the country. Between June 1995 and August 2006, a total of 128 patients underwent HSCT in this center, averaging about 10-12 transplants per year. The median age of these patients was 11 years (2 months to 45 years). Hematologic malignancies (49%) and inherited disorders (42%) constituted the major transplant indications, whereas BM failure accounted for the remaining. The majority of transplants carried out so far have been HLA-matched sibling-donor allogeneic HSCTs. Among the inherited disorders, homozygous beta-thalassemia and primary immunodeficiency are important transplant indications in this center. The approximate cost of an uncomplicated transplant in this center is US$50000. The success of this program has now led to the initiation of a new and larger HSCT complex to provide the opportunity for more patients to benefit from this treatment modality within the country.

UR - http://www.scopus.com/inward/record.url?scp=50549102512&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=50549102512&partnerID=8YFLogxK

U2 - 10.1038/bmt.2008.131

DO - 10.1038/bmt.2008.131

M3 - Article

C2 - 18724280

AN - SCOPUS:50549102512

VL - 42

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

IS - SUPPL.1

ER -